# Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease

> **NCT02437422** · PHASE1 · COMPLETED · sponsor: **Prolong Pharmaceuticals** · enrollment: 5 (actual)

## Conditions studied

- Renal Insufficiency, Chronic

## Interventions

- **BIOLOGICAL:** SANGUINATE

## Key facts

- **NCT ID:** NCT02437422
- **Lead sponsor:** Prolong Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-05
- **Primary completion:** 2015-11-18
- **Final completion:** 2015-11-18
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2018-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02437422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02437422, "Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02437422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*